- Home
- Publications
- Publication Search
- Publication Details
Title
Enterotoxins can support CAR T cells against solid tumors
Authors
Keywords
-
Journal
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 116, Issue 50, Pages 25229-25235
Publisher
Proceedings of the National Academy of Sciences
Online
2019-11-26
DOI
10.1073/pnas.1904618116
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD40 Agonist Antibodies in Cancer Immunotherapy
- (2019) Robert H. Vonderheide Annual Review of Medicine
- Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial
- (2018) Gregory L. Beatty et al. GASTROENTEROLOGY
- CAR T Cells in Trials: Recent Achievements and Challenges that Remain in the Production of Modified T Cells for Clinical Applications
- (2018) Ulrike Köhl et al. HUMAN GENE THERAPY
- Understanding the tumor immune microenvironment (TIME) for effective therapy
- (2018) Mikhail Binnewies et al. NATURE MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
- (2018) A. J. Davenport et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma
- (2018) Tomas Garzon-Muvdi et al. Oncotarget
- Phosphoproteomic analysis of chimeric antigen receptor signaling reveals kinetic and quantitative differences that affect cell function
- (2018) Alexander I. Salter et al. Science Signaling
- CD137 (4-1BB) Signalosome: Complexity Is a Matter of TRAFs
- (2018) Juan M. Zapata et al. Frontiers in Immunology
- Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
- (2017) Cameron J. Turtle et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
- (2017) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
- (2016) Clare Y. Slaney et al. CLINICAL CANCER RESEARCH
- Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells
- (2016) Lenka V. Hurton et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer
- (2016) Katelyn T. Byrne et al. Cell Reports
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
- (2015) Nabil Ahmed et al. JOURNAL OF CLINICAL ONCOLOGY
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma
- (2015) R. Winograd et al. Cancer Immunology Research
- Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice
- (2015) Carmen S. M. Yong et al. PLoS One
- 4-1BB Chimeric Antigen Receptors
- (2014) Dario Campana et al. CANCER JOURNAL
- The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity
- (2014) S. M. Mangsbo et al. CLINICAL CANCER RESEARCH
- Targeting Antigen to MHC Class II Molecules Promotes Efficient Cross-Presentation and Enhances Immunotherapy
- (2014) N. Dickgreber et al. JOURNAL OF IMMUNOLOGY
- A modified superantigen rescues Ly6G−CD11b+blood monocyte suppressor function and suppresses antigen-specific inflammation in EAE
- (2013) Clare Y. Slaney et al. AUTOIMMUNITY
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
- (2013) J. N. Kochenderfer et al. BLOOD
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
- (2013) Gabriela Bindea et al. IMMUNITY
- Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
- (2013) David S. Ritchie et al. MOLECULAR THERAPY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- Antigen Targeting to Major Histocompatibility Complex Class II with Streptococcal Mitogenic Exotoxin Z-2 M1, a Superantigen-Based Vaccine Carrier
- (2012) Fiona J. Radcliff et al. Clinical and Vaccine Immunology
- Artificial Antigen-Presenting Cells for Use in Adoptive Immunotherapy
- (2010) Cameron J. Turtle et al. CANCER JOURNAL
- In vivo Administration of Artificial Antigen-Presenting Cells Activates Low-Avidity T Cells for Treatment of Cancer
- (2009) S. Ugel et al. CANCER RESEARCH
- The bacterial superantigen and superantigen-like proteins
- (2008) John D. Fraser et al. IMMUNOLOGICAL REVIEWS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation